Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
161.51
+0.92 (0.57%)
After Hours: 162.70 +1.19 (0.74%)
Jan 29, 6:18PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 158.60 - 161.79
52 week 106.00 - 162.80
Open 160.07
Vol / Avg. 0.00/2.07M
Mkt cap 54.12B
P/E 109.28
Div/yield     -
EPS 1.48
Shares 333.57M
Beta 0.86
Inst. own 59%
Feb 25, 2015
Q4 2014 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 13, 2015
Valeant Pharmaceuticals International Inc at JPMorgan Healthcare Conference Q&A session
Jan 13, 2015
Valeant Pharmaceuticals International Inc at JPMorgan Healthcare Conference
Jan 8, 2015
Valeant Pharmaceuticals International Inc 2015 Financial Guidance Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 13.44% -14.97%
Operating margin 33.26% -8.22%
EBITD margin - 51.28%
Return on average assets 4.03% -3.76%
Return on average equity 21.28% -19.60%
Employees 17,200 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.

Officers and directors

J. Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Howard Bradley Schiller Chief Financial Officer, Executive Vice President, Director
Age: 52
Bio & Compensation  - Reuters
Pavel Mirovsky President and General Manager - Europe
Age: 63
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development
Age: 43
Bio & Compensation  - Reuters
Ari Kellen Executive Vice President, Company Group Chairman
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 43
Bio & Compensation  - Reuters
Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer
Age: 38
Bio & Compensation  - Reuters
Ryan H. Weldon Executive Vice President, Company Group Chairman
Age: 36
Bio & Compensation  - Reuters
Robert A. Ingram Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Jeffrey W. Ubben Director
Age: 54
Bio & Compensation  - Reuters